COLON DYSBIOSIS AND CHRONIC KIDNEY DISEASE

DOI: https://doi.org/10.29296/25877305-2019-02-02
Download full text PDF
Issue: 
2
Year: 
2019

M. Barilko(1); P. Seliverstov(2), Candidate of Medical Sciences, Professor V. Radchenko(2), MD 1-L.G. Sokolov Clinical Hospital One Hundred and Twenty-Two, Federal Biomedical Agency, Saint Petersburg 2-I.I. Mechnikov North-Western State Medical University, Saint. Petersburg

The colon microbiota was investigated in patients with chronic kidney disease (CKD) and manifestations of renal failure. Colon dysbiosis was detected in all the patients, which was manifested predominantly by the proteolytic flora of enteropathogenic Escherichia coli, Enterobacter spp./Citrobacter spp., and clinically by the symptoms of intestinal dyspepsia (symptoms of tympanism and constipation). The use of Laminolact in CKD patients normalizes the colon microbiota and reduces the manifestations of renal failure.
Keywords: 
nephrology
gastroenterology
dysbiosis
intestinal microbiocenosis
chronic kidney disease
uremic toxins
endotoxin
probiotics
prebiotics
synbiotics

It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.

References: 
  1. Bello A., Levin A., Tonelli M. et al. Assessment of Global Kidney Health Care Status // JAMA. – 2017; 317 (18): 1864–81.
  2. Smirnov A.V., Shilov E.M., Dobronravov V.A. i dr. Hronicheskaja bolezn' pochek: osnovnye printsipy skrininga, diagnostiki, profilaktiki i podhody k lecheniju. Natsional'nye rekomendatsii / SPb: Izdatel'stvo «Levsha», 2012; 51 s. [Smirnov A.V., Shilov E.M., Dobronravov V.A., et al. National Guidelines. Chronic kidney disease: basic principles of screening, diagnosis, prevention and treatment approaches / Saint-Petersburg: Levsha, 2012 (in Russ.)].
  3. Wong J., Piceno Y., De Santis T. et al. Expansion of urease and uricase-containing, indole- and p-cresol-forming and contraction of short chain fatty acid-producing intestinal bacteria in ESRD // Am. J. Nephrol. – 2014; 39: 230–7.
  4. McIntype C., Harrison L., Eldehni M. et al. Circulating endotoxemia: a novel factor in systemic inflammation and cardiovascular disease in chronic kidney disease // Clin. J. Am. Soc. Nephrol. – 2011; 6 (1): 133–41.
  5. Anders H., Andersen K., Stecher B. The intestinal microbiota, a leaky gut, and abnormal immunity in kidney disease // Kidney Int. – 2013; 83: 1010–6.
  6. Evenepoel P., Poesen R. The gut-kidney axis // Pediatr. Nephrol. – 2016; 32 (11): 2005–14.
  7. Meijers B., Evenepoel P. The gut-kidney axis: indoxyl sulfate, p-cresyl sulfate and CKD progression // Nephrol. Dial. Transplant. – 2011; 26: 759–61.
  8. Cosola C., Rocchetti M., Sabatino A. et al. Microbiota issue in CKD: how promising are gut-targeted approaches? // J. Nephrol. – 2018. DOI: 10.1007/s40620-018-0516-0 [Epub ahead of print]
  9. Pahl M., Vaziri N. The chronic kidney disease – colonic axis // Seminars in Dialysis. – 2015; 1–5.
  10. Vaziri N.D. Gut microbial translocation in the pathogenesis of systemic inflammation in patients with end-stage renal disease // Dig. Dis. Sci. – 2014; 59 (9): 2020–2.
  11. Aktual'nye voprosy korrektsii mikrobiotsenoza kishechnika. Uchebno-metodicheskoe posobie. Pod red. V.G. Radchenko, V.P. Dobritsa, P.V. Seli-verstova, L.A. Teterinoj, E.A. Chihachevoj / SPb, 2012; 20 s. [Topical issues of gut microbiota correction. Educational and methodical manual. Ed. V. Radchenko, V.Dobritsa, P. Seliverstov, L. Teterina, E. Chikhacheva / St. Petersburg, 2012; 20 s. (in Russ.)]
  12. Khodor S., Shatat I. Gut microbiome and kidney disease: a bidirectional relationship // Pediatr. Nephrol. – 2017; 32: 921–31.
  13. Pan W., Kang Y. Gut microbiota and chronic kidney disease: implications for novel mechanistic insights and therapeutic strategies // Int. Urol. Nephrol. – 2018; 50 (2): 289–99.
  14. Mafra D., Lobo J., Barros A. et al. Role of altered intestinal microbiota in systemic inflammation and cardiovascular disease in chronic kidney disease // Future Microbiology. – 2014; 9 (3): 399–410.
  15. Khoury T., Tzukert K., Abel R. et al. The gut-kidney axis in chronic renal failure: A new potential target for therapy // Hemodialysis International. – 2017; 21: 323–34.
  16. Beto J., Ramirez W., Bansal V. Medical nutrition therapy in adults with chronic kidney disease: integrating evidence and consensus into practice for the generalist registered dietitian nutritionist // J. Acad. Nutr. Diet. – 2014; 114 (7): 1077–87.
  17. Sredstva dlja korrektsii disbioza: funktsional'noe pitanie. Pod red. A.N. Suvorova / SPb, 2015; 15 s. [Medications for the correction of dysbiosis: functional nutrition. Ed. A. Suvorov / SPb, 2015; 15 s. (in Russ.)].
  18. Sabatino A. et al. Alterations of intestinal barrier and microbiota in chronic kidney disease // Nephrol. Dial. Transplant. – 2015; 30: 924–33.
  19. Wong J., Piceno Y., De Santis T. Expansion of urease and uricase-containing, indole- and p-cresol-forming and contraction of short chain fatty acid-producing intestinal bacteria in ESRD // Am. J. Nephrol. – 2014; 39: 230–7.
  20. Ajtbaev K.A., Murkamilov I.T., Kaliev R.R. Hronicheskaja bolezn' pochek: patofiziologicheskaja rol' disbioza kishechnika i renoprotektivnaja effektivnost' vmeshatel'stv po ego moduljatsii // Ros. med. zhurn. – 2016; 22 (3): 157–62 [Aytbaev K.A., Murkamilov I.T., Kaliev R.R. The chronic disease of kidneys: pathophysiological role of dysbiosis of intestine and renoprotective effectiveness of interventions concerning its modulation // Rossiiskii meditsinskii zhournal (Medical Journal of the Russian Federation, Russian journal). – 2016; 22 (3): 157–62 (in Russ.)]. DOI 10.18821/0869-2106-2016-22-3-157-162
  21. Vaziri N. CKD impairs barrier function and alters microbial flora of the intestine: a major link to inflammation and uremic toxicity // Curr. Opin. Nephrol. Hypert. – 2012; 21: 587–92.
  22. Wyss M., Kaddurah-Daouk R. Creatine and creatinine metabolism // Physiological Rev. – 2000; 80 (3): 1119–21, 1173–6.
  23. Radchenko V.G., Seliverstov P.V., Zagorodnikova K.A. i dr. Pat.2646467 RFMPK A61K 35/66; A61P 13/12. Cposob lechenija bol'nyh hronicheskoj bolezn'ju pochek S3-S5 na dodializnom etape, iskljuchaja pielonefrity, mochekamennuju bolezn'. №2017113189; Zajavl. 17.04.2017; Opubl. 5.03.2018. Bjul. №7: 18 s. [Radchenko V., Seliverstov P., Zagorodnikova K. et al. Pat.2646467RFMPC A61K 35/66; A61P 13/12. Method of treating patients with chronic kidney disease of the predialysis stage C3-C5, excluding pyelonephritis, urolithiasis. No. 2017113189; Claims 04/17/2017; Publ. 03/05/2018. Bul. No. 7: 18 with. No. 2017113189 (in Russ.)].